Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887353 · ClinicalTrials.gov registry record · Phase 2
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
A Phase 2 study, sponsored by Intermountain Health Care.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01887353: Clinical Trial Phase 2 study, sponsored by Intermountain Health Care.
NCT01887353 is a Phase 2 study that was terminated before completion, run by Intermountain Health Care. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01887353, a Phase 2 study, was terminated before completion, sponsored by Intermountain Health Care.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
Primary Outcome
There were too few participants for an assessment of time to first recurrence, therefore the numbers of participants with recurrence up to 6 months is reported instead
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Why NCT01887353 stopped before completion
NCT01887353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01887353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01887353 about?
NCT01887353 is a clinical study titled "The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure". The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
What is the current status of trial NCT01887353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01887353?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01887353?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01887353's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia